Developer docs
API playgroundTry for free, no card

Search company profiles

Lexogen

Full company profile

uuid0008s4d

Namestring
Lexogen
Legal namestring
Lexogen GmbH
Websiteurl
lexogen.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Lexogen GmbH is a Vienna-headquartered biotechnology company founded in 2007 that develops and commercializes RNA sequencing (RNA-Seq) library preparation kits, reagents, and related next-generation sequencing (NGS) services for transcriptome analysis. Its core technology portfolio spans whole-transcriptome library prep (CORALL), 3' mRNA-Seq expression profiling (QuantSeq), high-definition single-cell 3' mRNA-Seq (LUTHOR), metabolic RNA labeling (SLAMseq), rRNA depletion (RiboCop), small RNA-Seq (miRVEL), and spike-in controls (SIRVs), all produced under ISO 13485 quality standards. The company complements its kit business with full-service NGS offerings — including whole transcriptome, single-cell, FFPE, blood, plant, small RNA, ultra-low input, and DNA sequencing — plus bioinformatics services and the Kangooroo cloud-based data analysis platform.

Lexogen serves academic and research institutions, pharmaceutical and biotechnology companies, and clinical laboratories, with documented engagements including Stanford Medical School, Goethe-University Frankfurt, invIOs GmbH, and Ochre Bio. The business model is hybrid: one-time catalog and quote-based sales of kits and consumables through a direct webshop, email, phone, and fax ordering, combined with usage-based per-sample NGS service pricing and an annual subscription tier for the Kangooroo analytics platform. Commercial reach is global — a wholly-owned US subsidiary (Lexogen, Inc., Greenland, NH) with four regional sales territories, plus a trained distributor network covering more than 50 countries — while strategic partnerships with Cytosurge (Live-seq single-cell), Ochre Bio (human liver functional genomics), and BigOmics Analytics (downstream analytics) extend the technology and data footprint.

Short descriptiontext

Lexogen GmbH is a Vienna-based biotechnology company that develops RNA-Seq library preparation kits, NGS sequencing services, and bioinformatics tools for academic researchers, pharmaceutical and biotech firms, and clinical laboratories across more than 50 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersVienna, Austria
HQ citystring
Vienna
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA sequencing kits, NGS library preparation, transcriptomics services, single-cell RNA-Seq, bioinformatics analysis
Industry2 codes
1Transcriptomics & Gene Expression Profiling Services
CodeHLAGANAEPrimaryYes
2Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
CodeHLAGAIAFPrimaryNo
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
RNA Sequencing Reagents
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1RNA-Seq Kit Products
TypeOne Time License
Description

Sale of RNA sequencing library preparation kits, reagents, and consumables including CORALL, QuantSeq, LUTHOR, SLAMseq, RiboCop, miRVEL, and related products. Products are sold directly through the online store and through distributors in 50+ countries.

lexogen.com
2NGS Services
TypeProfessional Services
Description

Comprehensive next-generation sequencing services including gene expression profiling, whole transcriptome sequencing, FFPE RNA sequencing, blood RNA sequencing, plant RNA sequencing, small RNA sequencing, single-cell RNA sequencing, ultra-low input RNA sequencing, DNA sequencing, and custom bioinformatics solutions. Services are priced per sample with project-based quotes.

lexogen.com
3Bioinformatics/Data Analysis
TypeSubscription Recurring
Description

Data analysis services including Kangooroo platform access, Lexogen Bioinformatics Service, and custom bioinformatics solutions. Complementary to kit purchases or available as standalone service.

lexogen.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1RNA-Seq Library Prep Kits - Product catalog with catalog numbers available for all products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price per kit unit; specific pricing requires quote request via [email protected] or through distributor network

lexogen.com
2NGS Services - Per-sample and project-based pricing
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Services priced per sample with customizable scope; quotes provided based on sample number, service scope, and project requirements; pilot projects available before main projects

lexogen.com
3Kangooroo Data Analysis Platform - Cloud-based analysis for Lexogen kit users
ModelSubscriptionBilling cadenceAnnual
Notes

Use complementary with purchase of Lexogen RNA-Seq kits; subscription-based for standalone access

lexogen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Kangooroo
Description

Cloud-based data analysis platform for interactive visualization of expression studies, complementary to Lexogen RNA-Seq kits.

lexogen.com
Core offering1 text field

Lexogen develops and manufactures proprietary RNA sequencing (RNA-Seq) library preparation kits—including CORALL, QuantSeq, LUTHOR, SLAMseq, RiboCop, and miRVEL—and provides end-to-end next-generation sequencing services spanning gene expression profiling, whole transcriptome, single-cell, FFPE, blood, small RNA, and ultra-low input applications. The company also offers the Kangooroo cloud-based data analysis platform and custom bioinformatics solutions for research and drug discovery customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • STL001 FOXM1 inhibitor study: Whole transcriptome RNA-Seq using RiboCop rRNA Depletion and CORALL RNA-Seq confirmed mechanism of action and identified novel activities
+2 more records
Product overview1 text field

Lexogen offers an integrated portfolio of RNA analysis solutions comprising library preparation kits and NGS services. The core product lines include CORALL (whole transcriptome), QuantSeq 3' mRNA-Seq (expression profiling), miRVEL (small RNA-Seq), and LUTHOR (single-cell 3' mRNA-Seq) library prep kits. Supporting products include SLAMseq for metabolic labeling, RiboCop rRNA depletion, spike-in controls (SIRVs), RNA extraction/stabilization tools, and cDNA amplification kits. The NGS Services division provides wet lab sequencing services across applications including whole transcriptome, single-cell, FFPE, blood, plant, small RNA, ultra-low input, and drug sequencing, complemented by the Kangooroo cloud-based data analysis platform and custom bioinformatics solutions. Together, these offerings provide end-to-end workflows from sample preparation through data analysis.

Product and service10 records
1CORALL Total and mRNA-Seq Library Prep Kits
CategoryRNA Sequencing Kits
Description

Whole transcriptome library preparation kits for total RNA and mRNA sequencing, enabling comprehensive gene expression analysis for academic and pharmaceutical researchers.

2QuantSeq 3' mRNA-Seq Library Prep Kits
CategoryRNA Sequencing Kits
Description

3' end-focused mRNA sequencing library prep kits optimized for cost-effective gene expression profiling from various sample types.

3LUTHOR High-Definition Single-Cell 3' mRNA-Seq
CategoryRNA Sequencing Kits
Description

Single-cell RNA sequencing solution for high-definition 3' mRNA expression profiling at individual cell resolution.

4miRVEL Small RNA-Seq Library Prep Kit
CategoryRNA Sequencing Kits
Description

Small RNA sequencing library preparation kit for profiling microRNAs and other small non-coding RNAs with improved speed and reproducibility.

5SLAMseq Metabolic RNA Labeling Kit
CategoryRNA Sequencing Kits
Description

Metabolic RNA labeling kit for time-resolved RNA sequencing to distinguish newly synthesized transcripts and study RNA metabolism and dynamics.

6RiboCop rRNA Depletion Kits
CategoryRNA Sequencing Kits
Description

Ribosomal RNA depletion kits for removal of rRNA from total RNA samples to enrich for mRNA and non-coding RNAs in NGS workflows.

7SIRVs Spike-In RNA Variant Control Mixes
CategoryRNA Sequencing Kits
Description

Spike-in RNA variant control mixes used as internal standards in RNA-Seq experiments to monitor technical variability and normalize data.

8Lexogen NGS Services
CategoryNGS Services
Description

Comprehensive next-generation sequencing services spanning gene expression profiling, whole transcriptome, single-cell, FFPE, blood, plant, small RNA, ultra-low input, high-throughput drug, and DNA sequencing applications for research institutions, pharmaceutical companies, and biotech firms.

9Kangooroo NGS Data Analysis Platform
CategoryBioinformatics Software
Description

Cloud-based interactive data visualization and analysis platform for expression studies generated with Lexogen RNA-Seq kits, supporting collaborative bioinformatics workflows.

10Lexogen Bioinformatics Service and Custom Bioinformatics Solutions
CategoryBioinformatics Services
Description

Bioinformatics data analysis service for processing and interpreting NGS data with standard pipelines or tailored custom solutions designed for specific research project requirements.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-15
Description

Partnership to build one of the world's largest human liver functional genomics datasets to date. Lexogen provides NGS services for Ochre Bio's functional genomics research, supporting target identification in drug discovery. The collaboration focuses on advancing human liver research and therapeutic development through high-quality transcriptomic data.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

Cytosurge launched Live-seq, a single-cell RNA sequencing technology based on FluidFM fluidic force microscopy, developed in collaboration with academic partners. Lexogen provides RNA analysis services for the technology, partnering to offer the service for academic and industry researchers. The partnership enhances Cytosurge's platform performance and market adoption through Lexogen's RNA sequencing expertise.

Strategic tierSecondaryTypeTechnology or Integration
Description

Lexogen technologies (RiboCop rRNA Depletion and CORALL RNA-Seq) used in research published in collaboration with BigOmics. BigOmics' Omics Playground platform provides advanced data analysis for RNA-Seq experiments. The partnership enables researchers to access integrated wet lab and bioinformatics solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bio-Techne (through its RNA-Seq kit portfolio including the formerly exiqon brand) competes directly with Lexogen in RNA library preparation, small RNA analysis, and gene expression profiling reagents sold to academic and pharma researchers.

TypeDirect peer
Description

Qiagen offers competing NGS library prep kits (e.g., QIAseq) for RNA sequencing, targeted RNA panels, and related sample preparation consumables, making it a direct comparable in research and translational genomics.

TypeDirect peer
Description

NEB provides RNA-Seq library prep kits (e.g., NEBNext) and rRNA depletion reagents that directly overlap with Lexogen's CORALL, QuantSeq, and RiboCop product lines.

TypeDirect peer
Description

Takara Bio offers a portfolio of RNA-Seq library prep kits (SMARTer) and single-cell solutions that overlap directly with Lexogen's LUTHOR and whole-transcriptome offerings, particularly in academic and single-cell markets.

TypeBroad incumbent
Description

Illumina is the dominant NGS instrument provider with an expanding library prep and RNA-Seq reagent portfolio; its platform-driven reach and bundled offerings make it a broad incumbent in the same end markets as Lexogen.

TypeBroad incumbent
Description

Thermo Fisher competes through its Ion Torrent and RNA-Seq reagents plus bioinformatics, serving the same research and translational customer base as Lexogen with broader catalog and global reach.

TypeDirect peer
Description

10x Genomics is a leader in single-cell RNA sequencing with Chromium kits; Lexogen's LUTHOR high-definition single-cell 3' mRNA-Seq directly competes for share in single-cell transcriptomics workflows.

TypeEmerging player
Description

Parse Biosciences provides scalable single-cell RNA-Seq solutions (Evercode) targeting translational and academic customers, partially overlapping with Lexogen's single-cell kit and service offerings.

TypeBroad incumbent
Description

Revvity offers genomics reagents and NGS services across academic and clinical research, positioning it as a broader incumbent adjacent to Lexogen's RNA-focused kit and service portfolio.

TypeEmerging player
Description

Olink provides targeted proteomics and adjacent omics tools used in biomarker and translational research, representing an emerging player in the broader multi-omics workflows where Lexogen's RNA-Seq customers also operate.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lexogen

RNA Sequencing Reagentslexogen.com

Lexogen GmbH is a Vienna-based biotechnology company that develops RNA-Seq library preparation kits, NGS sequencing services, and bioinformatics tools for academic researchers, pharmaceutical and biotech firms, and clinical laboratories across more than 50 countries.

What Lexogen does

Lexogen GmbH is a Vienna-headquartered biotechnology company founded in 2007 that develops and commercializes RNA sequencing (RNA-Seq) library preparation kits, reagents, and related next-generation sequencing (NGS) services for transcriptome analysis. Its core technology portfolio spans whole-transcriptome library prep (CORALL), 3' mRNA-Seq expression profiling (QuantSeq), high-definition single-cell 3' mRNA-Seq (LUTHOR), metabolic RNA labeling (SLAMseq), rRNA depletion (RiboCop), small RNA-Seq (miRVEL), and spike-in controls (SIRVs), all produced under ISO 13485 quality standards. The company complements its kit business with full-service NGS offerings — including whole transcriptome, single-cell, FFPE, blood, plant, small RNA, ultra-low input, and DNA sequencing — plus bioinformatics services and the Kangooroo cloud-based data analysis platform.

Lexogen serves academic and research institutions, pharmaceutical and biotechnology companies, and clinical laboratories, with documented engagements including Stanford Medical School, Goethe-University Frankfurt, invIOs GmbH, and Ochre Bio. The business model is hybrid: one-time catalog and quote-based sales of kits and consumables through a direct webshop, email, phone, and fax ordering, combined with usage-based per-sample NGS service pricing and an annual subscription tier for the Kangooroo analytics platform. Commercial reach is global — a wholly-owned US subsidiary (Lexogen, Inc., Greenland, NH) with four regional sales territories, plus a trained distributor network covering more than 50 countries — while strategic partnerships with Cytosurge (Live-seq single-cell), Ochre Bio (human liver functional genomics), and BigOmics Analytics (downstream analytics) extend the technology and data footprint.

Lexogen firmographics

Firmographics
Name
Lexogen
Legal name
Lexogen GmbH
Website
https://lexogen.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Lexogen GmbH is a Vienna-based biotechnology company that develops RNA-Seq library preparation kits, NGS sequencing services, and bioinformatics tools for academic researchers, pharmaceutical and biotech firms, and clinical laboratories across more than 50 countries.
Ownership category
akta.pro rank

Lexogen industry classification

Industry
Product category
RNA Sequencing Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Transcriptomics & Gene Expression Profiling Services (HLAGANAE)
akta.pro secondary industry
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

  • RNA sequencing kits
  • NGS library preparation
  • Transcriptomics services
  • Single-cell RNA-Seq
  • Bioinformatics analysis

Where Lexogen is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
Austria
HQ region
Europe

Offices2 records

Markets served

Lexogen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. RNA-Seq Kit Products: Sale of RNA sequencing library preparation kits, reagents, and consumables including CORALL, QuantSeq, LUTHOR, SLAMseq, RiboCop, miRVEL, and related products. Products are sold directly through the online store and through distributors in 50+ countries.
  2. NGS Services: Comprehensive next-generation sequencing services including gene expression profiling, whole transcriptome sequencing, FFPE RNA sequencing, blood RNA sequencing, plant RNA sequencing, small RNA sequencing, single-cell RNA sequencing, ultra-low input RNA sequencing, DNA sequencing, and custom bioinformatics solutions. Services are priced per sample with project-based quotes.
  3. Bioinformatics/Data Analysis: Data analysis services including Kangooroo platform access, Lexogen Bioinformatics Service, and custom bioinformatics solutions. Complementary to kit purchases or available as standalone service.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRNA-Seq Library Prep Kits - Product catalog with catalog numbers available for all products
Usage-basedPay-as-you-goNGS Services - Per-sample and project-based pricing
SubscriptionAnnualKangooroo Data Analysis Platform - Cloud-based analysis for Lexogen kit users

Go-to-market motion1 record

Distribution channels6 records

Marketing channels11 records

Lexogen product offering

Product offering

Core offering

Lexogen develops and manufactures proprietary RNA sequencing (RNA-Seq) library preparation kits—including CORALL, QuantSeq, LUTHOR, SLAMseq, RiboCop, and miRVEL—and provides end-to-end next-generation sequencing services spanning gene expression profiling, whole transcriptome, single-cell, FFPE, blood, small RNA, and ultra-low input applications. The company also offers the Kangooroo cloud-based data analysis platform and custom bioinformatics solutions for research and drug discovery customers.

Product overview

Lexogen offers an integrated portfolio of RNA analysis solutions comprising library preparation kits and NGS services. The core product lines include CORALL (whole transcriptome), QuantSeq 3' mRNA-Seq (expression profiling), miRVEL (small RNA-Seq), and LUTHOR (single-cell 3' mRNA-Seq) library prep kits. Supporting products include SLAMseq for metabolic labeling, RiboCop rRNA depletion, spike-in controls (SIRVs), RNA extraction/stabilization tools, and cDNA amplification kits. The NGS Services division provides wet lab sequencing services across applications including whole transcriptome, single-cell, FFPE, blood, plant, small RNA, ultra-low input, and drug sequencing, complemented by the Kangooroo cloud-based data analysis platform and custom bioinformatics solutions. Together, these offerings provide end-to-end workflows from sample preparation through data analysis.

Differentiator

Problem solved

Functional benefit

Brands

  • Kangooroo: Cloud-based data analysis platform for interactive visualization of expression studies, complementary to Lexogen RNA-Seq kits.

Products and services

  • CORALL Total and mRNA-Seq Library Prep Kits Whole transcriptome library preparation kits for total RNA and mRNA sequencing, enabling comprehensive gene expression analysis for academic and pharmaceutical researchers.
  • QuantSeq 3' mRNA-Seq Library Prep Kits 3' end-focused mRNA sequencing library prep kits optimized for cost-effective gene expression profiling from various sample types.
  • LUTHOR High-Definition Single-Cell 3' mRNA-Seq Single-cell RNA sequencing solution for high-definition 3' mRNA expression profiling at individual cell resolution.
  • miRVEL Small RNA-Seq Library Prep Kit Small RNA sequencing library preparation kit for profiling microRNAs and other small non-coding RNAs with improved speed and reproducibility.
  • SLAMseq Metabolic RNA Labeling Kit Metabolic RNA labeling kit for time-resolved RNA sequencing to distinguish newly synthesized transcripts and study RNA metabolism and dynamics.
  • RiboCop rRNA Depletion Kits Ribosomal RNA depletion kits for removal of rRNA from total RNA samples to enrich for mRNA and non-coding RNAs in NGS workflows.
  • SIRVs Spike-In RNA Variant Control Mixes Spike-in RNA variant control mixes used as internal standards in RNA-Seq experiments to monitor technical variability and normalize data.
  • Lexogen NGS Services Comprehensive next-generation sequencing services spanning gene expression profiling, whole transcriptome, single-cell, FFPE, blood, plant, small RNA, ultra-low input, high-throughput drug, and DNA sequencing applications for research institutions, pharmaceutical companies, and biotech firms.
  • Kangooroo NGS Data Analysis Platform Cloud-based interactive data visualization and analysis platform for expression studies generated with Lexogen RNA-Seq kits, supporting collaborative bioinformatics workflows.
  • Lexogen Bioinformatics Service and Custom Bioinformatics Solutions Bioinformatics data analysis service for processing and interpreting NGS data with standard pipelines or tailored custom solutions designed for specific research project requirements.

Quantifiable outcome

  • STL001 FOXM1 inhibitor study: Whole transcriptome RNA-Seq using RiboCop rRNA Depletion and CORALL RNA-Seq confirmed mechanism of action and identified novel activities
  • +2 more outcomes

Companies that use Lexogen

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Lexogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Lexogen partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and secondary.

  • Ochre BiocoreStrategic or Co-development Partner · 15 December 2025Partnership to build one of the world's largest human liver functional genomics datasets to date. Lexogen provides NGS services for Ochre Bio's functional genomics research, supporting target identification in drug discovery. The collaboration focuses on advancing human liver research and therapeutic development through high-quality transcriptomic data.
  • CytosurgecoreStrategic or Co-development Partner · 28 October 2025Cytosurge launched Live-seq, a single-cell RNA sequencing technology based on FluidFM fluidic force microscopy, developed in collaboration with academic partners. Lexogen provides RNA analysis services for the technology, partnering to offer the service for academic and industry researchers. The partnership enhances Cytosurge's platform performance and market adoption through Lexogen's RNA sequencing expertise.
  • BigOmics AnalyticssecondaryTechnology or IntegrationLexogen technologies (RiboCop rRNA Depletion and CORALL RNA-Seq) used in research published in collaboration with BigOmics. BigOmics' Omics Playground platform provides advanced data analysis for RNA-Seq experiments. The partnership enables researchers to access integrated wet lab and bioinformatics solutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Lexogen competitors and assessment

Company assessment

Direct peers

  • Bio-Techne: Bio-Techne (through its RNA-Seq kit portfolio including the formerly exiqon brand) competes directly with Lexogen in RNA library preparation, small RNA analysis, and gene expression profiling reagents sold to academic and pharma researchers.
  • Qiagen: Qiagen offers competing NGS library prep kits (e.g., QIAseq) for RNA sequencing, targeted RNA panels, and related sample preparation consumables, making it a direct comparable in research and translational genomics.
  • New England Biolabs: NEB provides RNA-Seq library prep kits (e.g., NEBNext) and rRNA depletion reagents that directly overlap with Lexogen's CORALL, QuantSeq, and RiboCop product lines.
  • Takara Bio: Takara Bio offers a portfolio of RNA-Seq library prep kits (SMARTer) and single-cell solutions that overlap directly with Lexogen's LUTHOR and whole-transcriptome offerings, particularly in academic and single-cell markets.
  • 10x Genomics: 10x Genomics is a leader in single-cell RNA sequencing with Chromium kits; Lexogen's LUTHOR high-definition single-cell 3' mRNA-Seq directly competes for share in single-cell transcriptomics workflows.

Broad incumbents

  • Illumina: Illumina is the dominant NGS instrument provider with an expanding library prep and RNA-Seq reagent portfolio; its platform-driven reach and bundled offerings make it a broad incumbent in the same end markets as Lexogen.
  • Thermo Fisher Scientific: Thermo Fisher competes through its Ion Torrent and RNA-Seq reagents plus bioinformatics, serving the same research and translational customer base as Lexogen with broader catalog and global reach.
  • Revvity (formerly PerkinElmer): Revvity offers genomics reagents and NGS services across academic and clinical research, positioning it as a broader incumbent adjacent to Lexogen's RNA-focused kit and service portfolio.

Emerging players

  • Parse Biosciences: Parse Biosciences provides scalable single-cell RNA-Seq solutions (Evercode) targeting translational and academic customers, partially overlapping with Lexogen's single-cell kit and service offerings.
  • Olink Holding: Olink provides targeted proteomics and adjacent omics tools used in biomarker and translational research, representing an emerging player in the broader multi-omics workflows where Lexogen's RNA-Seq customers also operate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Lexogen social profiles

Digital presence

Lexogen compliance and trust

Trust signal

Compliance1 record

Lexogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lexogen leadership team

Management profile

Number of profiles

Profiles2 records

Lexogen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Lexogen funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lexogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lexogen

What does Lexogen do?

Lexogen develops and manufactures proprietary RNA sequencing (RNA-Seq) library preparation kits—including CORALL, QuantSeq, LUTHOR, SLAMseq, RiboCop, and miRVEL—and provides end-to-end next-generation sequencing services spanning gene expression profiling, whole transcriptome, single-cell, FFPE, blood, small RNA, and ultra-low input applications. The company also offers the Kangooroo cloud-based data analysis platform and custom bioinformatics solutions for research and drug discovery customers.

Is Lexogen a public or private company?

Lexogen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lexogen founded?

Lexogen was founded in 2007. It employs 101 to 250 people.

Where is Lexogen based?

Lexogen is headquartered in Vienna, Austria, in the Europe region.

How does Lexogen make money?

Three revenue lines are on record. RNA-Seq Kit Products are the primary driver. The others are NGS Services and bioinformatics/Data Analysis.

Who are Lexogen's main competitors?

Direct peers on record are Bio-Techne, Qiagen, New England Biolabs, Takara Bio and 10x Genomics. Broad incumbents are Illumina, Thermo Fisher Scientific and Revvity (formerly PerkinElmer). Emerging players are Parse Biosciences and Olink Holding.

Does Lexogen have an API?

No public API is recorded for Lexogen.

What industry is Lexogen in?

Lexogen's product category is RNA Sequencing Reagents. Its primary akta.pro industry code is HLAGANAE, Transcriptomics & Gene Expression Profiling Services, with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 325413 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireSeven RNA leaders launch the European RNA AllianceSeven European RNA companies launched the European RNA Alliance (ERA) to provide a shared gateway to complementary RNA expertise. The non-equity alliance aims to improve access to European RNA technologies and strengthen Europe's competitiveness, with each member retaining independence.PRLogPythia BioSciences & Lexogen Partner to Unify Multi-Omics Data Curation and Analytics with Bulk andPythia BioSciences and Lexogen announced a strategic partnership on July 21, 2026, combining Lexogen's RNA sequencing and wet-lab capabilities with Pythia's multi-omics data curation and analytics platform to accelerate drug discovery for biopharma researchers. The partnership unifies advanced analytics and standardized data curation workflows with Lexogen's custom wet-lab data generation, addressing limitations in public repositories such as sparse treatment metadata and small patient cohorts. The CEOs of both companies stated the collaboration will expand high-quality RNA-seq datasets and enable more data-driven biological research.Labiotech.euHow human-first datasets are reshaping AI drug discoveryBiotech companies Ochre Bio and Lexogen have formed a collaboration to generate one of the world's largest human liver functional genomics datasets for AI-driven drug discovery, using large-scale gene perturbation experiments in primary human hepatocytes across multiple donors and disease states. The companies argue that AI drug discovery is bottlenecked not by algorithms but by data quality, as many biological datasets remain correlational rather than causal, and animal models often fail to predict human clinical outcomes. The FDA announced in April 2025 a plan to reduce animal testing requirements in favor of human-based methodologies including AI models and organoids, potentially supporting adoption of these approaches.PR NewswireLexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug DiscoveryLexogen, a Vienna-based biotechnology company specializing in RNA sequencing, was featured in Labiotech's Beyond Biotech podcast alongside Ochre Bio, where CEO Dr. Stéphane Barges discussed the role of transcriptomics and high-quality datasets in advancing AI-driven drug discovery. The episode explored how specialized data generation supports target identification and the shift from animal to human research models. The podcast is available on major streaming platforms.PR NewswireLexogen Featured in Labiotech's Beyond Biotech Podcast on AI-Driven Drug DiscoveryLexogen CEO Dr. Stéphane Barges appeared alongside Ochre Bio CEO Dr. Quin Wills on Labiotech's Beyond Biotech podcast to discuss the role of RNA sequencing and transcriptomics in advancing AI-driven drug discovery. The conversation explored how high-quality, AI-optimized datasets built with scientific precision can improve target identification and reduce failure rates in therapeutic development. The podcast episode is available on major streaming platforms.openPR.comCompetitive Landscape: Leading Companies and New Entrants in the NGS-Based RNA-Sequencing MarketThe NGS-based RNA-sequencing market is projected to reach $12.73 billion by 2030 with a compound annual growth rate of 24.7%, driven by wider adoption in clinical diagnostics, precision medicine investments, and pharmaceutical research. In November 2024, French private equity firm ARCHIMED SAS acquired U.S.-based SeqCenter LLC to scale its next-generation sequencing capabilities and support global expansion. In October 2025, Austria-based biotech company Lexogen GmbH launched its miRVEL Profiling Small RNA-Seq Library Prep Kit, enabling ready-to-sequence libraries in under seven hours with minimal manual effort.PR NewswireLexogen schließt erfolgreich ein groß angelegtes Next-Gen-Sequenzierungsprojekt für menschliche Primärzellen mit Ochre Bio abLexogen, a Vienna-based biotech company specializing in RNA transcriptomics, has completed a large-scale data generation project with Ochre Bio, analyzing more than 120,000 primary human hepatocyte samples using its proprietary extraction-free, high-resolution gene expression profiling platform and NGS services. Ochre Bio is utilizing the high-accuracy RNA-Seq data to power its AI-driven target identification platform for developing RNA-based medicines targeting underserved chronic liver diseases. The partnership underscores Lexogen's role as a reliable sequencing provider delivering high-quality, reproducible data at scale under cGLP and ISO 13485 standards.PR NewswireLexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre BioLexogen, a Vienna-based biotech company specializing in RNA transcriptomics, has completed a large-scale data generation project with Ochre Bio, assessing over 120,000 samples from primary human hepatocytes using its proprietary extraction-free gene expression profiling platform and NGS Services. The project supports Ochre Bio's AI-driven target discovery platform for developing RNA medicines targeting chronic liver diseases, with high-fidelity RNA-Seq data serving as the foundational data source. Both companies emphasize the importance of rigorous data quality and cross-sample consistency for enabling accurate machine-learning models in drug discovery.PR NewswireLexogen achève avec succès un projet de séquençage nouvelle génération à grande échelle sur des cellules primaires humaines avec Ochre BioLexogen, a Vienna-based biotechnology company specializing in ARN transcriptomics, completed a large-scale next-generation sequencing project in partnership with Ochre Bio, evaluating over 120,000 samples of primary human hepatocytes using their proprietary THOR expression profiling platform without extraction. The project provided high-quality ARN sequencing data to support Ochre Bio's AI-driven target discovery platform for chronic liver disease RNA therapies. This collaboration exemplifies the growing convergence between advanced sequencing technologies and AI-powered drug discovery in the biotech sector.PR NewswireLexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre BioLexogen, a Vienna-based biotech company specializing in RNA transcriptomics, announced the completion of a large-scale sequencing project with Ochre Bio, assessing over 120,000 samples of primary human hepatocytes using Lexogen's proprietary extraction-free THOR technology and NGS services. The high-fidelity RNA-Seq data generated supports Ochre Bio's AI-driven target discovery platform for developing RNA medicines targeting chronic liver diseases. Lexogen CEO Stephane Barges emphasized the company's commitment to delivering reliable, high-quality data at scale to support partners advancing healthcare discoveries.